Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Alzheimer's Disease

Free Subscription Articles published in JAMA Retrieve available abstracts of 49 articles: HTML format

Single Articles

April 2024
1. RUBIN R
   Could GLP-1 Receptor Agonists like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?
   JAMA. 2024 Apr 19. doi: 10.1001/jama.2024.1017.
   PubMed    
   
   
   March 2024
2. KO D, Pascual-Leone A, Shah SJ
   Use of Lecanemab for Patients With Cardiovascular Disease: The Challenge of Uncertainty.
   JAMA. 2024 Mar 15. doi: 10.1001/jama.2024.2991.
   PubMed    
   
   
   
3. HARRIS E
   Biomarker Changes Can Begin 18 Years Before Alzheimer Disease Diagnosis.
   JAMA. 2024 Mar 6. doi: 10.1001/jama.2024.1568.
   PubMed    
   
   
   February 2024
4. HARRIS E
   Aducanumab Combined With Focused Brain Ultrasound More Effective.
   JAMA. 2024;331:466-467.
   PubMed    
   
   
   
5. HARRIS E
   Commercial Blood Test May Identify Alzheimer Disease Brain Pathology.
   JAMA. 2024 Feb 7. doi: 10.1001/jama.2024.0175.
   PubMed    
   
   
   December 2023
6. POMARA N, Imbimbo BP
   Use of Donanemab in Early Symptomatic Alzheimer Disease.
   JAMA. 2023;330:2304.
   PubMed    
   
   
   
7. EVANS CD, Sims JR
   Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.
   JAMA. 2023;330:2304-2305.
   PubMed    
   
   
   November 2023
8. RAFII MS, Fortea J
   Down Syndrome in a New Era for Alzheimer Disease.
   JAMA. 2023 Nov 22. doi: 10.1001/jama.2023.22924.
   PubMed    
   
   
   September 2023
9. RUBIN R
   Who Should-and Can-Get Lecanemab, the New Alzheimer Disease Drug?
   JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.14443.
   PubMed    
   
   
   
10. ODOUARD IC, Socal MP, Anderson GF
    Role of Registries in Medicare Coverage of New Alzheimer Disease Drugs.
    JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.17131.
    PubMed    
    
    
    
11. RUBIN R
    Consumers Can Now Buy a Blood Test to Evaluate Their Alzheimer Disease Risk, but Should They?
    JAMA. 2023 Sep 13. doi: 10.1001/jama.2023.17685.
    PubMed    
    
    
    August 2023
12. HARRIS E
    Study: Identifying Lewy Body Disease Before Symptoms.
    JAMA. 2023;330:686.
    PubMed    
    
    
    July 2023
13. HARRIS E
    MIND Diet No Better Than Control for Adults at Risk of Dementia.
    JAMA. 2023 Jul 26. doi: 10.1001/jama.2023.13134.
    PubMed    
    
    
    
14. HARRIS E
    Alzheimer Drug Lecanemab Gains Traditional FDA Approval.
    JAMA. 2023 Jul 19. doi: 10.1001/jama.2023.12548.
    PubMed    
    
    
    
15. SIMS JR, Zimmer JA, Evans CD, Lu M, et al
    Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
    JAMA. 2023 Jul 17:e2313239. doi: 10.1001/jama.2023.13239.
    PubMed     Abstract available
    
    
    
16. ROSENTHAL MB
    Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11702.
    PubMed    
    
    
    
17. MANLY JJ, Deters KD
    Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11704.
    PubMed    
    
    
    
18. RABINOVICI GD, La Joie R
    Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11703.
    PubMed    
    
    
    
19. WIDERA EW, Brangman SA, Chin NA
    Ushering in a New Era of Alzheimer Disease Therapy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11701.
    PubMed    
    
    
    
20. HARRIS E
    More Lean Muscle Might Reduce Alzheimer Disease Risk.
    JAMA. 2023 Jul 12. doi: 10.1001/jama.2023.12544.
    PubMed    
    
    
    June 2023
21. HARRIS E
    CMS Will Cover Alzheimer Drugs With Traditional FDA Approval.
    JAMA. 2023 Jun 14. doi: 10.1001/jama.2023.10400.
    PubMed    
    
    
    
22. HARRIS E
    Brain Cell Biomarker for Preclinical Alzheimer Disease Identified.
    JAMA. 2023 Jun 7. doi: 10.1001/jama.2023.9928.
    PubMed    
    
    
    May 2023
23. HARRIS E
    FDA Greenlights First Drug for Agitation Related to Alzheimer Disease.
    JAMA. 2023 May 24. doi: 10.1001/jama.2023.9153.
    PubMed    
    
    
    
24. MARCUS R
    New Alzheimer Disease Drugs, Long COVID and the Central Nervous System, and a Nasal Spray for Migraines-Highlights From the 2023 American Academy of Neurology Conference.
    JAMA. 2023 May 10. doi: 10.1001/jama.2023.4389.
    PubMed    
    
    
    March 2023
25. HARRIS E
    Blood Biomarker Helps Distinguish Vascular Dementia.
    JAMA. 2023;329:969.
    PubMed    
    
    
    February 2023
26. HARRIS E
    Healthful Lifestyle May Slow Memory Loss, Even for APOE Gene Carriers.
    JAMA. 2023;329:622.
    PubMed    
    
    
    
27. LE GUEN Y, Raulin AC, Logue MW, Sherva R, et al
    Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer Disease.
    JAMA. 2023;329:551-560.
    PubMed     Abstract available
    
    
    January 2023
28. LARKIN HD
    Lecanemab Gains FDA Approval for Early Alzheimer Disease.
    JAMA. 2023 Jan 18. doi: 10.1001/jama.2022.24490.
    PubMed    
    
    
    
29. LARKIN H
    Noninvasive Sensory Stimulation With Light and Sound Tested in Alzheimer Disease.
    JAMA. 2023;329:114.
    PubMed    
    
    
    September 2022
30. HARRIS E
    Large Autopsy Study Estimates Prevalence of "LATE" Neuropathologic Change.
    JAMA. 2022;328:815-816.
    PubMed    
    
    
    August 2022
31. RUBIN R
    Much Anticipated Alzheimer Disease Prevention Trial Finds No Clinical Benefit From Drug Targeting Amyloid; Highlights Need to Consider Other Approaches.
    JAMA. 2022 Aug 17. pii: 2795592. doi: 10.1001/jama.2022.11490.
    PubMed    
    
    
    
32. DEPEW R
    To My Husband With Alzheimer Disease.
    JAMA. 2022;328:587.
    PubMed    
    
    
    
33. SLOMSKI A
    Anti-Tau Antibody Semorinemab Fails to Slow Alzheimer Disease.
    JAMA. 2022;328:415.
    PubMed    
    
    
    July 2022
34. SURAN M
    Some Antioxidants May Mitigate the Risk of Dementias.
    JAMA. 2022;328:321.
    PubMed    
    
    
    June 2022
35. RUBIN R
    New Test to Help Diagnose Alzheimer Disease.
    JAMA. 2022;327:2281.
    PubMed    
    
    
    May 2022
36. LARKIN HD
    First Donepezil Transdermal Patch Approved for Alzheimer Disease.
    JAMA. 2022;327:1642.
    PubMed    
    
    
    December 2021
37. SLOMSKI A
    Methylphenidate Treats Apathy in Alzheimer Disease.
    JAMA. 2021;326:2120.
    PubMed    
    
    
    October 2021
38. EMANUEL EJ
    A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
    JAMA. 2021;326:1367-1368.
    PubMed    
    
    
    September 2021
39. ANDERSON TS, Ayanian JZ, Souza J, Landon BE, et al
    Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
    JAMA. 2021 Sep 9. pii: 2784225. doi: 10.1001/jama.2021.15286.
    PubMed    
    
    
    August 2021
40. RUBIN R
    CMS Considers Controversial Alzheimer Drug Coverage.
    JAMA. 2021;326:690.
    PubMed    
    
    
    July 2021
41. RUBIN R
    Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.
    JAMA. 2021 Jul 21. pii: 2782427. doi: 10.1001/jama.2021.11558.
    PubMed    
    
    
    
42. SCHULMAN KA, Greicius MD, Richman B
    Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
    JAMA. 2021 Jul 19. pii: 2782333. doi: 10.1001/jama.2021.11768.
    PubMed    
    
    
    June 2021
43. CHEN MH, Yang FC, Liang CS
    APOE Allele Testing and Alzheimer Disease.
    JAMA. 2021;325:2210-2211.
    PubMed    
    
    
    
44. CHOUDHURY P, Ramanan VK, Boeve BF
    APOE Allele Testing and Alzheimer Disease-Reply.
    JAMA. 2021;325:2211.
    PubMed    
    
    
    April 2021
45. RUBIN R
    Neurologist Faces His Alzheimer Diagnosis Determined to Lessen Stigma Surrounding the Disease.
    JAMA. 2021 Apr 28. pii: 2779452. doi: 10.1001/jama.2021.5333.
    PubMed    
    
    
    March 2021
46. ALEXANDER GC, Emerson S, Kesselheim AS
    Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
    JAMA. 2021 Mar 30. pii: 2778191. doi: 10.1001/jama.2021.3854.
    PubMed    
    
    
    January 2021
47. CHOUDHURY P, Ramanan VK, Boeve BF
    APOE varepsilon4 Allele Testing and Risk of Alzheimer Disease.
    JAMA. 2021 Jan 14. pii: 2775399. doi: 10.1001/jama.2020.15085.
    PubMed    
    
    
    November 2020
48. MADDOX M
    Alzheimer Aubade.
    JAMA. 2020;324:2108.
    PubMed    
    
    
    October 2020
49. TSOU AY, Bulova P, Capone G, Chicoine B, et al
    Medical Care of Adults With Down Syndrome: A Clinical Guideline.
    JAMA. 2020;324:1543-1556.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.